3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Lymphoid
2
Classical hematology
2
Conditions
Neoplasms
2
Febrile Neutropenia
2
Sepsis
1
Emergencies
1
Interventions
Epoetin Alfa
25
Darbepoetin alfa
17
apixaban
9
Rivaroxaban
9
Dalteparin
7
Heparin, Low-Molecular-Weight
6
Surveys and Questionnaires
5
Meropenem
5
fludarabine phosphate
4
Vancomycin
4
Tinzaparin
4
Enoxaparin
4
Cyclosporine
4
Cefepime
4
ferric carboxymaltose
3
edoxaban
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Ceftazidime
3
Carboplatin
3
Busulfan
3
Antilymphocyte Serum
3
Amikacin
3
romiplostim
2
peginesatide
2
hematide
2
fludarabine
2
epoetin beta
2
bemiparin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Amoxicillin-Potassium Clavulanate Combination
×
Classical hematology
×
Clear all
NCT05393505
2022-12-06
FRANCiS-NF
The University of Hong Kong
Phase 4
Unknown
344 enrolled
NCT03003273
2019-02-01
DALFEN
All India Institute of Medical Sciences
Phase 3
Terminated
142 enrolled